sutacimig

Sutacimig (formerly known as HMB-001) is a subcutaneously administered bispecific antibody developed as a first-in-class prophylactic treatment for Glanzmann thrombasthenia (GT), a rare and severe bleeding disorder. The drug works by binding and stabilizing endogenous Factor VIIa with one antibody arm while the other arm binds to TLT-1 on activated platelets. This dual mechanism allows for the accumulation of endogenous Factor VIIa in the body and its targeted recruitment to activated platelets, facilitating hemostatic plug formation at sites of vascular injury. Sutacimig is designed to address significant unmet needs in GT, where no effective prophylactic treatments currently exist, and has potential applications in other bleeding disorders such as Factor VII Deficiency and Von Willebrand Disease. The drug has received Fast Track Designation and Orphan Drug Designation from the FDA for GT, as well as ILAP designation from the UK MHRA[1][2][4][6][7].

Other names

sutacimigHMB-001HMB001HMB 001